PL373943A1 - Therapeutic use of selective pde10 inhibitors - Google Patents

Therapeutic use of selective pde10 inhibitors

Info

Publication number
PL373943A1
PL373943A1 PL03373943A PL37394303A PL373943A1 PL 373943 A1 PL373943 A1 PL 373943A1 PL 03373943 A PL03373943 A PL 03373943A PL 37394303 A PL37394303 A PL 37394303A PL 373943 A1 PL373943 A1 PL 373943A1
Authority
PL
Poland
Prior art keywords
therapeutic use
pde10 inhibitors
selective pde10
selective
inhibitors
Prior art date
Application number
PL03373943A
Other languages
English (en)
Polish (pl)
Inventor
Lorraine Ann Lebel
Frank Samuel Menniti
Christopher Joseph Schmidt
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/139,183 external-priority patent/US20030018047A1/en
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of PL373943A1 publication Critical patent/PL373943A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/44—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving esterase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/30—Psychoses; Psychiatry
    • G01N2800/301—Anxiety or phobic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/30—Psychoses; Psychiatry
    • G01N2800/302—Schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
PL03373943A 2002-05-03 2003-04-22 Therapeutic use of selective pde10 inhibitors PL373943A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/139,183 US20030018047A1 (en) 2001-04-20 2002-05-03 Therapeutic use of selective PDE10 inhibitors
US10/177,018 US20030032579A1 (en) 2001-04-20 2002-06-20 Therapeutic use of selective PDE10 inhibitors

Publications (1)

Publication Number Publication Date
PL373943A1 true PL373943A1 (en) 2005-09-19

Family

ID=29406263

Family Applications (1)

Application Number Title Priority Date Filing Date
PL03373943A PL373943A1 (en) 2002-05-03 2003-04-22 Therapeutic use of selective pde10 inhibitors

Country Status (16)

Country Link
US (2) US20030032579A1 (OSRAM)
EP (1) EP1504118A2 (OSRAM)
JP (1) JP2005524402A (OSRAM)
KR (1) KR20040106455A (OSRAM)
CN (1) CN1668761A (OSRAM)
AU (1) AU2003222395A1 (OSRAM)
BR (1) BR0309746A (OSRAM)
CA (1) CA2484600A1 (OSRAM)
HR (1) HRP20041029A2 (OSRAM)
IL (1) IL164778A0 (OSRAM)
MX (1) MXPA04010777A (OSRAM)
NO (1) NO20044470L (OSRAM)
PL (1) PL373943A1 (OSRAM)
RU (1) RU2303259C2 (OSRAM)
TW (1) TWI269812B (OSRAM)
WO (1) WO2003093499A2 (OSRAM)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20060030483A (ko) * 2003-06-30 2006-04-10 알타나 파마 아게 Ｐｄｅ10 억제제로서 피롤로디히드로이소퀴놀린
CA2530114A1 (en) * 2003-06-30 2005-01-13 Altana Pharma Ag Pyrrolo-dihydroisoquinoline derivatives as pde10 inhibitors
JP2007523152A (ja) * 2004-02-18 2007-08-16 ファイザー・プロダクツ・インク キナゾリンおよびイソキノリンのテトラヒドロイソキノリニル誘導体
EP1755611A1 (en) * 2004-06-07 2007-02-28 Pfizer Products Inc. Phosphodiesterase 10 inhibition as treatment for obesity-related and metabolic syndrome-related conditions
US20060019975A1 (en) * 2004-07-23 2006-01-26 Pfizer Inc Novel piperidyl derivatives of quinazoline and isoquinoline
US7576080B2 (en) * 2004-12-23 2009-08-18 Memory Pharmaceuticals Corporation Certain thienopyrimidine derivatives as phosphodiesterase 10 inhibitors
EA012211B1 (ru) * 2005-01-07 2009-08-28 Пфайзер Продактс Инк. Гетероароматические соединения хинолинов и их применение в качестве ингибиторов pde10
ATE430148T1 (de) * 2005-01-12 2009-05-15 Nycomed Gmbh Neue pyrrolodihydroisochinoline als pde10- inhibitoren
JP2009535394A (ja) 2006-05-02 2009-10-01 ファイザー・プロダクツ・インク Ｐｄｅ１０阻害剤としての二環式ヘテロアリール化合物
TW200817400A (en) * 2006-05-30 2008-04-16 Elbion Ag Pyrido [3,2-e] pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them
TW200815436A (en) * 2006-05-30 2008-04-01 Elbion Ag 4-amino-pyrido[3,2-e]pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them
US20080090834A1 (en) * 2006-07-06 2008-04-17 Pfizer Inc Selective azole pde10a inhibitor compounds
US20100056791A1 (en) * 2006-09-01 2010-03-04 Yasushi Kohno Pyrazolopyridine carboxamide derivative and phosphodiesterase (pde) inhibitor containing the same
US20090318385A1 (en) * 2006-09-06 2009-12-24 Yasushi Kohno Pyrazolopyride derivative and phosphodiesterase ( pde) inhibitors containing the same as active ingredient
US7786139B2 (en) * 2006-11-21 2010-08-31 Omeros Corporation PDE10 inhibitors and related compositions and methods
US8637528B2 (en) 2007-03-27 2014-01-28 Omeros Corporation Use of PDE7 inhibitors for the treatment of movement disorders
WO2008119057A2 (en) * 2007-03-27 2008-10-02 Omeros Corporation The use of pde7 inhibitors for the treatment of movement disorders
US7858620B2 (en) 2007-09-19 2010-12-28 H. Lundbeck A/S Cyanoisoquinoline
WO2009068320A1 (en) * 2007-11-30 2009-06-04 Elbion Gmbh Aryl and heteroaryl fused imidazo (1,5-a) pyrazines as inhibitors of phosphodiesterase 10
US20090143361A1 (en) * 2007-11-30 2009-06-04 Elbion Gmbh Pyrido[3,2-E]Pyrazines, Process For Preparing The Same, And Their Use As Inhibitors Of Phosphodiesterase 10
WO2009070584A1 (en) * 2007-11-30 2009-06-04 Wyeth Aryl and heteroaryl fused imidazo[1,5-a]pyrazines as inhibitors of phosphodiesterase 10
WO2010145668A1 (en) 2009-06-19 2010-12-23 H. Lundbeck A/S Novel phenylimidazole derivative as pde10a enzyme inhibitor
BRPI0914772A2 (pt) 2008-06-25 2015-10-20 Envivo Pharmaceuticals Inc compostos heterocíclicos 1,2-dissubstituídos
WO2010006130A2 (en) 2008-07-09 2010-01-14 Envivo Pharmaceuticals, Inc. Pde-10 inhibitors
CN102143752B (zh) 2008-08-05 2014-12-10 奥默罗斯公司 Pde10抑制剂以及相关组合物和方法
EP2348018A4 (en) * 2008-09-25 2012-04-25 Kyorin Seiyaku Kk HETEROCYCLIC BIARYL DERIVATIVE AND PDE INHIBITOR CONTAINING ACTIVE SUBSTANCE
US20110224250A1 (en) * 2008-10-09 2011-09-15 Yasushi Kohno Isoquinoline derivative, and pde inhibitor comprising same as active ingredient
CA2761032A1 (en) 2009-05-07 2010-11-11 Envivo Pharmaceuticals, Inc. Phenoxymethyl heterocyclic compounds
US9468637B2 (en) 2009-05-13 2016-10-18 Intra-Cellular Therapies, Inc. Organic compounds
WO2010138833A1 (en) 2009-05-29 2010-12-02 Wyeth SUBSTITUTED IMIDAZO[1,5-a]QUINOXALINES AS INHIBITORS OF PHOSPHODIESTERASE 10
WO2010144416A1 (en) * 2009-06-08 2010-12-16 Gaeta Federico C A SUBSTITUTED PYRAZOLO [1,5-a] PYRIDINE COMPOUNDS HAVING MULTI-TARGET ACTIVITY
TWI485151B (zh) 2009-12-17 2015-05-21 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑之雜芳香族苯基咪唑衍生物
TW201200516A (en) 2009-12-17 2012-01-01 Lundbeck & Co As H Phenylimidazole derivatives comprising an ethynylene linker as PDE10A enzyme inhibitors
TWI487705B (zh) 2009-12-17 2015-06-11 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑之雜芳香族芳基三唑衍生物
TWI481607B (zh) 2009-12-17 2015-04-21 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑的２－芳基咪唑衍生物
NZ601967A (en) 2010-03-12 2015-03-27 Omeros Corp Pde10 inhibitors and related compositions and methods
TW201215607A (en) 2010-07-02 2012-04-16 Lundbeck & Co As H Aryl-and heteroarylamid derivatives as PDE10A enzyme inhibitor
TW201206935A (en) 2010-07-16 2012-02-16 Lundbeck & Co As H Triazolo-and pyrazoloquinazoline derivatives as PDE10A enzyme inhibitor
JO3089B1 (ar) 2010-11-19 2017-03-15 H Lundbeck As مشتقات ايميدازول كمثبطات لانزيمات pde10a
MX2013009575A (es) 2011-02-18 2014-10-14 Exonhit Therapeutics Sa Derivados de 6, 7-dialcoxi-3-isoquinolinol sustituidos como inhibidores de fosfodiesterasa 10 (pdei0a).
US8592423B2 (en) 2011-06-21 2013-11-26 Bristol-Myers Squibb Company Inhibitors of PDE10
US8975276B2 (en) 2011-06-29 2015-03-10 Bristol-Myers Squibb Company Inhibitors of PDE10
US9938269B2 (en) 2011-06-30 2018-04-10 Abbvie Inc. Inhibitor compounds of phosphodiesterase type 10A
WO2013045607A1 (en) 2011-09-30 2013-04-04 H. Lundbeck A/S Quinazoline linked heteroaromatic tricycle derivatives as pde10a enzyme inhibitors
WO2013050527A1 (en) 2011-10-05 2013-04-11 H. Lundbeck A/S Quinazoline derivatives as pde10a enzyme inhibitors
US20130116241A1 (en) 2011-11-09 2013-05-09 Abbvie Inc. Novel inhibitor compounds of phosphodiesterase type 10a
BR112014011173A2 (pt) 2011-11-09 2017-05-09 Abbvie Deutschland carboxamidas heterocíclicas úteis como inibidores de fosfodiesterase tipo 10a
TWI570124B (zh) 2011-12-21 2017-02-11 Ｈ 朗德貝克公司 作為ｐｄｅ１０ａ酵素抑制劑的喹啉衍生物
US9138494B2 (en) 2011-12-23 2015-09-22 Abbvie Inc. Radiolabeled PDE10A ligands
WO2013127817A1 (en) 2012-02-27 2013-09-06 H. Lundbeck A/S Imidazole derivatives as pde10a enzyme inhibitors
RU2657540C2 (ru) * 2012-06-26 2018-06-14 Янссен Фармацевтика Нв Комбинации, содержащие ингибиторы pde 2, такие как 1-арил-4-метил-[1,2,4]триазоло[4,3-а]хиноксалиновые соединения, и ингибиторы pde 10, для применения в лечении неврологических или метаболических расстройств
US9464085B2 (en) 2012-08-17 2016-10-11 AbbVie Deutschland GmbH & Co. KG Inhibitor compounds of phosphodiesterase type 10A
IN2015DN01900A (OSRAM) 2012-09-17 2015-08-07 Abbvie Deutschland
WO2014071044A1 (en) 2012-11-01 2014-05-08 Allergan, Inc. Substituted 6,7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (pde10a)
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
US9790203B2 (en) 2012-11-26 2017-10-17 Abbvie Inc. Inhibitor compounds of phosphodiesterase type 10A
HUE043059T2 (hu) 2013-02-27 2019-07-29 Mochida Pharm Co Ltd Új pirazolszármazék
US9200005B2 (en) 2013-03-13 2015-12-01 AbbVie Deutschland GmbH & Co. KG Inhibitor compounds of phosphodiesterase type 10A
WO2014140184A1 (en) 2013-03-14 2014-09-18 AbbVie Deutschland GmbH & Co. KG Novel inhibitor compounds of phosphodiesterase type 10a
US9200016B2 (en) 2013-12-05 2015-12-01 Allergan, Inc. Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A)
NZ716494A (en) 2014-04-28 2017-07-28 Omeros Corp Processes and intermediates for the preparation of a pde10 inhibitor
NZ716462A (en) 2014-04-28 2017-11-24 Omeros Corp Optically active pde10 inhibitor
CN107530313A (zh) 2015-04-24 2018-01-02 奥默罗斯公司 Pde10抑制剂以及相关组合物和方法
WO2017079678A1 (en) 2015-11-04 2017-05-11 Omeros Corporation Solid state forms of a pde10 inhibitor
US10682354B2 (en) 2016-03-28 2020-06-16 Intra-Cellular Therapies, Inc. Compositions and methods
US20210330736A1 (en) * 2018-09-05 2021-10-28 Universiteit Van Amsterdam Use of a pde11 or pde2 inhibitor for the treatment of parkinson's disease
CN110346004B (zh) * 2019-08-16 2020-08-21 杭州山科智能科技股份有限公司 一种双声道超声时差法的流量测量数据融合方法
US12544364B2 (en) 2020-06-05 2026-02-10 Noema Pharma Ag Use of a phosphodiesterase 10 inhibitor for the treatment of tourette syndrome
MX2022015400A (es) * 2020-06-05 2023-03-16 Noema Pharma Ag Uso del inhibidor de la fosfodiesterasa a 10 para el tratamiento del sindrome de tourette.
WO2022162193A1 (en) * 2021-01-28 2022-08-04 Noema Pharma Ag Methods for the treatment of childhood-onset fluency disorder

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ194348A (en) * 1979-07-26 1982-09-14 Merrell Toraude & Co Fluorinated methyl-beta-alanine derivatives and pharmaceutical compositions
DE3224100A1 (de) * 1982-06-29 1983-12-29 Michael 6950 Schriesheim Long Depotmedikament zur behandlung von psychologischen aberrationen, erkrankungen und dergleichen
EP0627219A1 (en) * 1993-05-25 1994-12-07 Daiichi Pharmaceutical Co., Ltd. Use of calmodulin inhibitors for neuroprotection
US5487976A (en) * 1993-10-15 1996-01-30 Cornell Research Foundation, Inc. DNA encoding an insect gamma-aminobutyric acid (GABA) receptor subunit cells expressing it, and pesticide screening methods using such cells
US20040152106A1 (en) * 1999-10-07 2004-08-05 Robertson Harold A. Gene necessary for striatal function, uses thereof, and compounds for modulating same
ES2256415T3 (es) * 2001-07-31 2006-07-16 Pfizer Products Inc. Ensayos basados en celulas y secuencias para la fosfodiesterasa 10a.

Also Published As

Publication number Publication date
WO2003093499A2 (en) 2003-11-13
KR20040106455A (ko) 2004-12-17
IL164778A0 (en) 2005-12-18
CN1668761A (zh) 2005-09-14
RU2303259C2 (ru) 2007-07-20
US20040162294A1 (en) 2004-08-19
HRP20041029A2 (en) 2004-12-31
WO2003093499A3 (en) 2004-04-22
BR0309746A (pt) 2007-03-27
EP1504118A2 (en) 2005-02-09
MXPA04010777A (es) 2005-03-07
NO20044470L (no) 2004-11-04
AU2003222395A1 (en) 2003-11-17
CA2484600A1 (en) 2003-11-13
TW200307751A (en) 2003-12-16
US20030032579A1 (en) 2003-02-13
TWI269812B (en) 2007-01-01
JP2005524402A (ja) 2005-08-18
RU2004132198A (ru) 2005-04-20

Similar Documents

Publication Publication Date Title
IL164778A0 (en) Therapeutic use of selective pde10 inhibitors
HUP0201310A3 (en) Therapeutic use of selective pde10 inhibitors
AU2003303128A8 (en) Inhibitors and methods of use thereof
EP1549316A4 (en) HAMMER OF TFGbeta
IL166780A0 (en) Use of ikappab-kinase inhibitors in pain therapy
EG27049A (en) P38 inhibitors and methods of use thereof
AU2003297691A8 (en) Devices and methods for selective orientation of electrosurgical devices
AU2003217870A8 (en) Pini-modulating compounds and methods of use thereof
EP1606283A4 (en) P38 INHIBITOR AND METHOD OF USE THEREOF
AU2003213673A8 (en) Pin1-modulating compounds and methods of use thereof
EP1511488A4 (en) HUMAN INHIBITORS OF ADAM 10
AU2002361861A8 (en) Selective 11beta-hsd inhibitors and methods for use thereof
GB0324761D0 (en) Use of compounds in therapy
IL165475A0 (en) Nitrooxyderivatives of eyclooxygenase-2 inhibitors
AU2003232848A8 (en) Phenylaminopyrimidines and their use as rho-kinase inhibitors
AU2003210983A8 (en) Kinase inhibitors and methods of use thereof
GB2408558B (en) Treatment of pipes
GB0219660D0 (en) Therapeutic use
GB0207410D0 (en) Compounds and their therapeutic use
PL397022A1 (pl) Środek leczniczy
GB0210741D0 (en) Methods of therapy
EP1569928A4 (en) THERAPEUTIC COMPOUNDS AND METHOD
IL160230A0 (en) Use of il-18 inhibitors
GB0221712D0 (en) Methods of treatment
GB0207409D0 (en) Benzofuran-2H-3-one compounds and their therapeutic use

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)